Literature DB >> 35836038

Improved Pharmaceutical Properties of Honokiol via Salification with Meglumine: an Exception to Oft-quoted ∆pKa Rule.

Xiaoshuang He1, Yuanfeng Wei1, Shiru Wang1, Jianjun Zhang2, Yuan Gao1, Shuai Qian3, Zunting Pang4, Weili Heng5.   

Abstract

Honokiol (HK), a BCS class II drug with a wide range of pharmacological activities, has poor solubility and low oral bioavailability, severely limiting its clinical application. In the current study, incorporating a water-soluble meglumine (MEG) into the crystal lattice of HK molecule was performed to improve its physicochemical properties. The binary mixture of HK and MEG was obtained by anti-solvent method and characterized by TGA, DSC, FTIR, and PXRD. The SCXRD analysis showed that two HK- molecules and two MEG+ molecules were coupled in each unit cell via the ionic interaction along with intermolecular hydrogen bonds, suggesting the formation of a salt, which was further confirmed by the XPS measurements. However, the ∆pKa value between HK and MEG was found to be less than 1, which did not follow the oft-quoted ∆pKa rule for salt formation. After salification with MEG, the solubility and dissolution rate of HK exhibited 3.50 and 25.33 times improvement than crystalline HK, respectively. Simultaneously, the powder flowability, tabletability and stability of HK-MEG salt was also significantly enhanced, and the salt was not more hygroscopic, and that salt formation did not compromise processability in that regard. Further, in vivo pharmacokinetic study showed that Cmax and AUC0-t of HK-MEG salt were enhanced by 2.92-fold and 2.01-fold compared to those of HK, respectively, indicating a considerable improvement in HK oral bioavailability.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Bioavailability; Honokiol; Meglumine; Physicochemical properties; Salification

Mesh:

Substances:

Year:  2022        PMID: 35836038     DOI: 10.1007/s11095-022-03335-6

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.580


  28 in total

1.  Studies on the active principles of magnolia bark. Centrally acting muscle relaxant activity of magnolol and hōnokiol.

Authors:  K Watanabe; H Y Watanabe; Y Goto; N Yamamoto; M Yoshizaki
Journal:  Jpn J Pharmacol       Date:  1975-10

2.  Preparation and Characterization of Honokiol Nanosuspensions and Preliminary Evaluation of Anti-Inflammatory Effect.

Authors:  Xinyue Lu; Xiaoyu Lu; Zhenhai Zhang; Huixia Lv
Journal:  AAPS PharmSciTech       Date:  2020-01-10       Impact factor: 3.246

3.  Multifunctional effects of honokiol as an anti-inflammatory and anti-cancer drug in human oral squamous cancer cells and xenograft.

Authors:  Jin Hyoung Cho; Young-Joo Jeon; Seon-Min Park; Jae-Cheon Shin; Tae-Hoon Lee; Seunggon Jung; Hongju Park; Joohyun Ryu; Hanyong Chen; Zigang Dong; Jung-Hyun Shim; Jung-Il Chae
Journal:  Biomaterials       Date:  2015-03-16       Impact factor: 12.479

4.  Improved solubility and pharmacokinetics of PEGylated liposomal honokiol and human plasma protein binding ability of honokiol.

Authors:  Xian-Huo Wang; Lu-Lu Cai; Xiao-Yan Zhang; Lin-Yu Deng; Hao Zheng; Chong-Yang Deng; Jiao-Lin Wen; Xia Zhao; Yu-Quan Wei; Li-Juan Chen
Journal:  Int J Pharm       Date:  2011-03-21       Impact factor: 5.875

Review 5.  Honokiol: a novel natural agent for cancer prevention and therapy.

Authors:  S Arora; S Singh; G A Piazza; C M Contreras; J Panyam; A P Singh
Journal:  Curr Mol Med       Date:  2012-12       Impact factor: 2.222

6.  UPLC-MS/MS-ESI assay for simultaneous determination of magnolol and honokiol in rat plasma: application to pharmacokinetic study after administration emulsion of the isomer.

Authors:  Yi-Ling Sheng; Jing-Hua Xu; Cai-Hong Shi; Wei Li; Hai-Yan Xu; Ning Li; Yu-Qing Zhao; Xiang-Rong Zhang
Journal:  J Ethnopharmacol       Date:  2014-08-04       Impact factor: 4.360

7.  Antioxidant Activity of Magnolol and Honokiol: Kinetic and Mechanistic Investigations of Their Reaction with Peroxyl Radicals.

Authors:  Riccardo Amorati; Julija Zotova; Andrea Baschieri; Luca Valgimigli
Journal:  J Org Chem       Date:  2015-10-16       Impact factor: 4.354

8.  Honokiol nanoparticles based on epigallocatechin gallate functionalized chitin to enhance therapeutic effects against liver cancer.

Authors:  Peixiao Tang; Qiaomei Sun; Hongqin Yang; Bin Tang; Hongyu Pu; Hui Li
Journal:  Int J Pharm       Date:  2018-04-30       Impact factor: 5.875

9.  Development of Nanosome-Encapsulated Honokiol for Intravenous Therapy Against Experimental Autoimmune Encephalomyelitis.

Authors:  Yai-Ping Hsiao; Hui-Ting Chen; Yu-Chih Liang; Tse-En Wang; Kai-Hung Huang; Cheng-Chih Hsu; Hong-Jen Liang; Chung-Hsiung Huang; Tong-Rong Jan
Journal:  Int J Nanomedicine       Date:  2020-01-06

Review 10.  Honokiol: An anticancer lignan.

Authors:  Abdur Rauf; Seema Patel; Muhammad Imran; Aneela Maalik; Muhammad Umair Arshad; Farhan Saeed; Yahia N Mabkhot; Salim S Al-Showiman; Nazir Ahmad; Eman Elsharkawy
Journal:  Biomed Pharmacother       Date:  2018-08-13       Impact factor: 6.529

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.